AOD-9604 has a clinical history that most vendor content leaves out. The compound entered human trials in the early 2000s and was tested in six clinical studies involving approximately 900 participants. The Phase IIa results were positive: 2.6 to 2.8 kg of additional weight loss versus 0.8 kg placebo over 12 weeks at 1 mg per day, in a trial of 300 participants. Those numbers are real.
What happened next is the part vendors do not mention. The pivotal Phase IIb trial, called OPTIONS, enrolled 536 participants over 24 weeks at multiple doses. The primary endpoint was statistically significant weight loss versus placebo. It failed at every dose tested. No statistically significant weight loss was detected at any dose versus placebo over 24 weeks. This was not a marginal miss. The pivotal trial, designed with adequate power to confirm the Phase IIa signal, found no effect.
Metabolic Pharmaceuticals terminated development in 2007. AOD-9604 has never been approved by the FDA, TGA, EMA, or any regulatory authority worldwide as a drug.
The Phase IIa/IIb pattern is well understood in drug development. Phase IIa is a smaller, shorter trial designed to detect a signal. Phase IIb is a larger, longer trial designed to confirm it. Positive Phase IIa results that fail to replicate in Phase IIb are common. This is exactly what happened with AOD-9604.
One contributing factor cited in the literature: the Phase IIb trial incorporated an intensive diet and exercise program in both arms, which may have reduced the drug-placebo difference. But this is the standard design for a weight loss trial. If a compound only works without lifestyle intervention, its clinical utility is limited.
Vendor marketing consistently cites the Phase IIa data (2.6 to 2.8 kg weight loss) without mentioning the Phase IIb failure. This is not incomplete information. It is misleading information. The Phase IIb result is the more rigorous, more relevant dataset and it is negative.
The regulatory status as of April 2026 is unambiguous: AOD-9604 cannot be legally compounded in the United States. The FDA placed it on the Category 2 interim bulks list in September 2023 (substances with significant safety concerns, banned from compounding). It was removed from Category 2 in September 2024 when the nominator withdrew. The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed it at the December 4, 2024 meeting and voted against recommending it for inclusion on the 503A bulks list.
PCAC votes are recommendations; the FDA must complete formal rulemaking. As of April 2026, AOD-9604 does not meet the criteria required for 503A compounding and may not be legally compounded. It is sold only as a research chemical through unregulated channels.
Some vendor marketing claims AOD-9604 has GRAS (Generally Recognized as Safe) status. This is technically true and practically misleading. The GRAS designation applies to food and dietary supplement oral use only. It does not constitute drug approval. It does not apply to injectable use. It does not override the FDA's compounding restrictions.
Citing GRAS status to imply safety for subcutaneous injection is the equivalent of noting that table salt is GRAS and using that to justify intravenous saline without a prescription. The contexts are not equivalent.
One thing the clinical data does establish clearly: AOD-9604 has a clean safety profile. Across six human trials and approximately 900 participants, no serious adverse events were detected. No immunogenicity. No IGF-1 changes. No glucose disruption. FAERS and CAERS searches through 2024 returned zero adverse event reports.
The safety data is the one area where vendor claims are supported by the evidence. The compound appears safe. It also appears ineffective for weight loss based on its own pivotal trial.
AOD-9604 is the most thoroughly human-tested weight loss peptide in the biohacker canon. It has more clinical trial data than BPC-157, TB-500, or any research peptide discussed in forums. And that data shows the compound failed its pivotal efficacy trial. The safety profile is genuinely clean. The weight loss efficacy is not validated. The regulatory status prohibits legal compounding. These three facts should be the starting point of any conversation about AOD-9604, not an afterthought.
Every Tuesday: one landmark study, one protocol, one regulatory update. Plus new research posts as they publish. Free.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use